Company Filing History:
Years Active: 2019
Title: Sensen Lai: Innovator in Anticoagulant Research
Introduction
Sensen Lai is a notable inventor based in Yunnan, China. He has made significant contributions to the field of biomedical research, particularly in the development of anticoagulant therapies. His innovative work focuses on low-molecular-weight glycosaminoglycan derivatives, which have potential applications in treating thrombotic diseases.
Latest Patents
Sensen Lai holds a patent for a low-molecular-weight fucosylated glycosaminoglycan (aTFG) that contains 2,5-anhydrated talose. This patent, titled "Low-molecular-weight glycosaminoglycan derivative containing terminal 2, 5-anhydrated talose or derivative thereof," describes a composition that includes alditol, glycosylamine, or N-substituted glycosylamine monosaccharides. The preparation method and pharmaceutical compositions containing aTFG are also detailed in the patent. The aTFG exhibits potent anticoagulant activity by targeting intrinsic coagulation factor Xase, thereby inhibiting thrombogenesis. This innovation holds promise for the prevention and treatment of cardiovascular and cerebrovascular diseases.
Career Highlights
Sensen Lai's career is marked by his dedication to advancing medical science through innovative research. His work has led to the development of novel therapeutic agents that can significantly impact patient care in the field of cardiovascular health. His expertise in glycosaminoglycan derivatives has positioned him as a key figure in this area of research.
Collaborations
Sensen Lai collaborates with esteemed colleagues, including Jinhua Zhao and Mingyi Wu. These partnerships enhance the research efforts and contribute to the advancement of their shared goals in biomedical innovation.
Conclusion
Sensen Lai's contributions to the field of anticoagulant research exemplify the impact of innovative thinking in medicine. His patented work on low-molecular-weight glycosaminoglycan derivatives showcases the potential for new treatments in thrombotic diseases. Through his research and collaborations, he continues to pave the way for advancements in cardiovascular health.